Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009
Active clinical pulmonary sarcoidosis is characterized by significantly reduced apoptosis rate of alveolar lymphocytes (AL) Source: Virtual Congress 2020 – Sarcoidosis: from genetics to epidemiology Year: 2020
Differences in alveolar cell populations, natural killer cells and lymphocyte subsets between pulmonary sarcoidosis (PS) and idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006
Enhanced apoptosis of alveolar lymphocytes (AL), but not macrophages (AM) in interstitial idiopathic pneumonias (IIPs). Special attention to idiopathic pulmonary fibrosis (IPF) results Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010
Activated lymphoid follicles, sign of an immune response, are present in early idiopathic pulmonary fibrosis (IPF) and increase with disease progression. Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021
Extensive alveoalar lymphocyte apoptosis in pulmonary sarcoidosis (PS) followed by clinical improvement. Two distinct apoptosis presentations? Source: Eur Respir J 2004; 24: Suppl. 48, 551s Year: 2004
Elevated apoptosis rate of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonitis (NSIP) – strong positive correlation with bronchoalvoelar lavage (BAL) neutrophil count. Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020
Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020
Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients? Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases Year: 2017
Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD) Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD Year: 2011
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016
Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR) Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation Year: 2020
Neutrophil-rich inflammation in induced sputum of patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2001; 18: Suppl. 33, 409s Year: 2001
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013
Does IFN-g slow progression of idiopathic pulmonary fibrosis (IPF)? Source: Eur Respir J 2005; 26: Suppl. 49, 335s Year: 2005
Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 354s Year: 2006
Safety of sputum induction (SI) in interstitial lung disease (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007
A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020
Effect of cigarette smoking on alveolar macrophages (AM) and lymphocytes (AL) apoptosis in selected interstitial lung diseases (ILD) Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008
The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD) Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005